158 related articles for article (PubMed ID: 33279289)
1. Outline of gelatinase inhibitors as anti-cancer agents: A patent mini-review for 2010-present.
Baidya SK; Amin SA; Jha T
Eur J Med Chem; 2021 Mar; 213():113044. PubMed ID: 33279289
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of gelatinases (MMP-2 and MMP-9) for the management of hematological malignancies.
Das S; Amin SA; Jha T
Eur J Med Chem; 2021 Nov; 223():113623. PubMed ID: 34157437
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of selective and blood-brain barrier-permeable hydroxamate-based gelatinase inhibitors.
Bertran A; Khomiak D; Konopka A; Rejmak E; Bulska E; Seco J; Kaczmarek L; Tarragó T; Prades R
Bioorg Chem; 2020 Jan; 94():103365. PubMed ID: 31676116
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, experimental evaluation and molecular modelling of hydroxamate derivatives as zinc metalloproteinase inhibitors.
Sjøli S; Nuti E; Camodeca C; Bilto I; Rossello A; Winberg JO; Sylte I; Adekoya OA
Eur J Med Chem; 2016 Jan; 108():141-153. PubMed ID: 26638045
[TBL] [Abstract][Full Text] [Related]
5. MMP-2 selectivity in hydroxamate-type inhibitors.
Serra P; Bruczko M; Zapico JM; Puckowska A; Garcia MA; Martin-Santamaria S; Ramos A; de Pascual-Teresa B
Curr Med Chem; 2012; 19(7):1036-64. PubMed ID: 22257051
[TBL] [Abstract][Full Text] [Related]
6. An integrated computational and experimental approach to gaining selectivity for MMP-2 within the gelatinase subfamily.
Fabre B; Filipiak K; Díaz N; Zapico JM; Suárez D; Ramos A; de Pascual-Teresa B
Chembiochem; 2014 Feb; 15(3):399-412. PubMed ID: 24449516
[TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview.
Mondal S; Adhikari N; Banerjee S; Amin SA; Jha T
Eur J Med Chem; 2020 May; 194():112260. PubMed ID: 32224379
[TBL] [Abstract][Full Text] [Related]
8. Halting Tumor Progression via Novel Non-Hydroxamate Triazole-Based Mannich Bases MMP-2/9 Inhibitors; Design, Microwave-Assisted Synthesis, and Biological Evaluation.
Albelwi FF; Teleb M; Abu-Serie MM; Moaty MNAA; Alsubaie MS; Zakaria MA; El Kilany Y; Aouad MR; Hagar M; Rezki N
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638665
[TBL] [Abstract][Full Text] [Related]
9. Gelatinase inhibitors: a patent review (2011-2017).
Li X
Expert Opin Ther Pat; 2018 Jan; 28(1):31-46. PubMed ID: 29130358
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of potent hydroxamate inhibitors with increased selectivity within the gelatinase family.
Zapico JM; Puckowska A; Filipiak K; Coderch C; de Pascual-Teresa B; Ramos A
Org Biomol Chem; 2015 Jan; 13(1):142-56. PubMed ID: 25348733
[TBL] [Abstract][Full Text] [Related]
11. Functional mimetic peptide discovery isolated by phage display interacts selectively to fibronectin domain and inhibits gelatinase.
Shoari A; Rasaee MJ; Kanavi MR; Daraei B
J Cell Biochem; 2019 Dec; 120(12):19699-19711. PubMed ID: 31270859
[TBL] [Abstract][Full Text] [Related]
12. Insight into the structural requirement of aryl sulphonamide based gelatinases (MMP-2 and MMP-9) inhibitors - Part I: 2D-QSAR, 3D-QSAR topomer CoMFA and Naïve Bayes studies - First report of 3D-QSAR Topomer CoMFA analysis for MMP-9 inhibitors and jointly inhibitors of gelatinases together.
Das S; Amin SA; Jha T
SAR QSAR Environ Res; 2021 Aug; 32(8):655-687. PubMed ID: 34355614
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological evaluation of 4-phenoxybenzenesulfonyl pyrrolidine derivatives as matrix metalloproteinase inhibitors.
Mao J; Zhang H; Wang X; Gao J; Tang J; Zhang J
Biosci Trends; 2020 Jul; 14(3):192-199. PubMed ID: 32389938
[TBL] [Abstract][Full Text] [Related]
14. N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity.
Nuti E; Cantelmo AR; Gallo C; Bruno A; Bassani B; Camodeca C; Tuccinardi T; Vera L; Orlandini E; Nencetti S; Stura EA; Martinelli A; Dive V; Albini A; Rossello A
J Med Chem; 2015 Sep; 58(18):7224-40. PubMed ID: 26263024
[TBL] [Abstract][Full Text] [Related]
15. Development of matrix metalloproteinase inhibitors in cancer therapy.
Hidalgo M; Eckhardt SG
J Natl Cancer Inst; 2001 Feb; 93(3):178-93. PubMed ID: 11158186
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and preliminary bioactivity evaluations of 8-hydroxyquinoline derivatives as matrix metalloproteinase (MMP) inhibitors.
Chen C; Yang X; Fang H; Hou X
Eur J Med Chem; 2019 Nov; 181():111563. PubMed ID: 31415980
[TBL] [Abstract][Full Text] [Related]
17. Identification of highly potent and selective MMP2 inhibitors addressing the S1' subsite with d-proline-based compounds.
Lenci E; Innocenti R; Di Francescantonio T; Menchi G; Bianchini F; Contini A; Trabocchi A
Bioorg Med Chem; 2019 May; 27(9):1891-1902. PubMed ID: 30926311
[TBL] [Abstract][Full Text] [Related]
18. The matrix metalloproteinase inhibitor marimastat promotes neural progenitor cell differentiation into neurons by gelatinase-independent TIMP-2-dependent mechanisms.
Sinno M; Biagioni S; Ajmone-Cat MA; Pafumi I; Caramanica P; Medda V; Tonti G; Minghetti L; Mannello F; Cacci E
Stem Cells Dev; 2013 Feb; 22(3):345-58. PubMed ID: 23098139
[TBL] [Abstract][Full Text] [Related]
19. Structure-Activity Relationships of UTX-121 Derivatives for the Development of Novel Matrix Metalloproteinase-2/9 Inhibitors.
Yamahana H; Komiya Y; Takino T; Endo Y; Yamada H; Asada C; Uto Y
Chem Pharm Bull (Tokyo); 2021; 69(10):1017-1028. PubMed ID: 34602570
[TBL] [Abstract][Full Text] [Related]
20. TGFbeta1 stimulates the secretion of matrix metalloproteinase 2 (MMP2) and the invasive behavior in human ovarian cancer cells, which is suppressed by MMP inhibitor BB3103.
Lin SW; Lee MT; Ke FC; Lee PP; Huang CJ; Ip MM; Chen L; Hwang JJ
Clin Exp Metastasis; 2000; 18(6):493-9. PubMed ID: 11592306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
